Insider · CIK 0001432078
Jacob D. Cohen
Files at MGRX (MANGOCEUTICALS, INC.). First filing -, latest -.
In brief
Jacob D. Cohen files SEC Form 4 as CEO, director and 10% owner at MGRX (MANGOCEUTICALS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jacob D. Cohen has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2025 | MGRX MANGOCEUTICALS, INC. | GGift Common Stock | -500,000 | $0.00 | $0 | 0 | 7 d ago |
| Sep 30, 2025 | MGRX MANGOCEUTICALS, INC. | GGift Common Stock | +500,000 | $0.00 | $0 | 1,305,000 | 7 d ago |
| Jul 28, 2026 | MGRX MANGOCEUTICALS, INC. | AGrant or award Common Stock | +2,000,000 | $0.00 | $0 | 2,000,000 | 7 d ago |
| Aug 11, 2026 | MGRX MANGOCEUTICALS, INC. | GGift Common Stock | -2,000,000 | $0.00 | $0 | 0 | 7 d ago |
| Aug 11, 2026 | MGRX MANGOCEUTICALS, INC. | GGift Common Stock | +2,000,000 | $0.00 | $0 | 3,305,000 | 7 d ago |
| Dec 19, 2025 | MGRX MANGOCEUTICALS, INC. | JOther Convertible Promissory Notederivative | - | $0.00 | - | - | 7 d ago |
| Jun 5, 2025 | MGRX MANGOCEUTICALS, INC. | GGift Common Stock | -200,000 | $0.00 | $0 | 0 | Mar 20, 2026 |
| Jun 5, 2025 | MGRX MANGOCEUTICALS, INC. | GGift Common Stock | +200,000 | $0.00 | $0 | 805,000 | Mar 20, 2026 |
| Mar 16, 2026 | MGRX MANGOCEUTICALS, INC. | DDisposition to issuer Stock Option (right to buy)derivative | -50,000 | $0.00 | $0 | 0 | Mar 20, 2026 |
| Sep 9, 2025 | MGRX MANGOCEUTICALS, INC. | AGrant or award Common Stock | +500,000 | $0.00 | $0 | 500,000 | Mar 20, 2026 |
| Mar 16, 2026 | MGRX MANGOCEUTICALS, INC. | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Mar 20, 2026 |
| Jul 21, 2025 | MGRX MANGOCEUTICALS, INC. | AGrant or award Convertible Promissory Notederivative | - | - | - | - | Mar 20, 2026 |
| Mar 16, 2026 | MGRX MANGOCEUTICALS, INC. | DDisposition to issuer Stock Option (right to buy)derivative | -83,333 | $0.00 | $0 | 0 | Mar 20, 2026 |
| Jul 21, 2025 | MGRX MANGOCEUTICALS, INC. | AGrant or award Warrant to Purchase Common Stockderivative | +50,000 | - | - | 50,000 | Mar 20, 2026 |
| Mar 16, 2026 | MGRX MANGOCEUTICALS, INC. | AGrant or award Stock Option (right to buy)derivative | +83,333 | $0.00 | $0 | 83,333 | Mar 20, 2026 |
| Sep 9, 2025 | MGRX MANGOCEUTICALS, INC. | AGrant or award Stock Option (right to buy)derivative | +2,000,000 | $0.00 | $0 | 2,000,000 | Mar 20, 2026 |
| Mar 16, 2026 | MGRX MANGOCEUTICALS, INC. | DDisposition to issuer Stock Option (right to buy)derivative | -2,000,000 | $0.00 | $0 | 0 | Mar 20, 2026 |
| Mar 16, 2026 | MGRX MANGOCEUTICALS, INC. | AGrant or award Stock Option (right to buy)derivative | +2,000,000 | $0.00 | $0 | 2,000,000 | Mar 20, 2026 |
| Apr 10, 2025 | MGRX MANGOCEUTICALS, INC. | AGrant or award Common Stock | +200,000 | $0.00 | $0 | 200,000 | Sep 30, 2025 |
| Apr 10, 2025 | MGRX MANGOCEUTICALS, INC. | AGrant or award Common Stock | +200,000 | $0.00 | $0 | 200,000 | Apr 11, 2025 |
Questions about Jacob D. Cohen
Answered from the filings on this page, as of the latest one.
Is Jacob D. Cohen buying or selling?
Jacob D. Cohen has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jacob D. Cohen's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jacob D. Cohen has 0.
Where does Jacob D. Cohen file Form 4?
Jacob D. Cohen has filed Form 4 at MGRX (MANGOCEUTICALS, INC.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.